Drug-Eluting Stents Beat Bare Metal Stents in...(rs found no safety differences between t...),Health

The Massachusetts Data Analysis Center (Mass-DAC) registry is a special resource to research outcomes after PCI, since the state department of public health requires that every non-federal hospital provide procedural information and outcomes for every adult who undergoes PCI. Such data are intended to monitor and to improve the quality of patient care.

"Through an effort headed by the Division of Health Care Quality at the Massachusetts Department of Public Health, we were able to use clinical data collected from every non-federal hospital in the state that treats patients with stents to monitor safety of the drug-eluting stents," said Sharon-Lise Normand, Ph.D., co-author of the study, director of the Mass-DAC and professor of health care policy (biostatistics) at Harvard Medical School and Harvard School of Public Health. "Surveillance systems such as this are critical to assessing quality and safety in the real-world."

Other co-authors are: Pallav Garg, M.B.B.S., M.Sc.; Treacy S. Silbaugh, B.Sc.; Robert E. Wolf, M.S.; Katya Zelevinsky, B.A.; Ann F. Lovett, R.N., M.A.; Manu R. Varma, B.S.; and Zheng Zhou, M.D., Ph.D. Individual author disclosures are available on the abstract.

The study was funded by Massachusetts Department of Public Health Contract 620022A4PRE.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict p
'/>"/>